Axon Ligands (TM) - alphabetic: [A] [B] [C] [D] [E] [F] [G] [H] [I] [J] [K] [L] [M] [N] [O] [P] [Q] [R] [S] [T] [U] [V] [W] [X] [Y] [Z]

CP 690550 

Tasocitinib - Tofacitinib

CAS 477600-75-2

C16H20N6O  MW 312.38

Purity: 99% (optically pure)

Soluble in DMSO to 100 mM

Ordering Information:

Cat. No. Axon 1338     Prime Source

Qty1: 2 mg (research sample) / €85  $111

Qty2: 5 mg (research sample) / €135  $176

Promotion: 2 x 5 mg @ €180  $234

Qty3: 25 mg (research sample) / €435  $566

Qty4: on request

Send enquiry to: order@axonmedchem.com

or by fax to: +31-50-3600390.

Contact us for payment and tech support.

Biological Activity:   Janus Kinase 3 (JAK3) inhibitor; an immunosuppressive agent exhibiting potent effects in preclinical transplantation and arthritis models; clinically safe and effective in preventing transplant rejection and improving symptoms of rheumatoid arthritis and psoriasis.   References: online 1, 2, 3, 4, 5   LA Sorbera et al. CP-690550, Drugs Fut. 2007, 32(8), 674.   AC Papageorgiou and LEK Wikman, Is JAK3 a new drug target for immunomodulation-based therapies? Trends Pharmacol. Sci. 2004, 25(11), 558-562.   E Kudlacz et al. The novel JAK-3 inhibitor CP-690550 is a potent immunosuppressive agent in various murine models. Am. J. Transplant. 2004, 4(1), 51-7.   E Kudlacz et al. The JAK-3 inhibitor CP-690550 is a potent anti-inflammatory agent in a murine model of pulmonary eosinophilia. Eur. J. Pharmacol. 2008, 582(1-3), 154-61.   PS Changelian et al. Prevention of Organ Allograft Rejection by a Specific Janus Kinase 3 Inhibitor. Sci. 2003, 302(5646), 875-878.     Chemical Name: 3-{(3R,4R)-4-Methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-1-yl}-3-oxo-propionitrile

CP 690550 | JAK3 inhibitor | Axon Medchem | Axon 1338 | Tasocitinib - CP690550 - Tofacitinib

Axon Ligands ^TM - Research chemicals for biological study. Some high-profile samples could be provided under terms of contract research synthesis.

axonmedchem.com © 2012